Prices delayed ≤15 min
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectab
Frequently Asked Questions about BMY
What does Bristol-Myers Squibb Company (BMY) do?
Bristol-Myers Squibb Company specializes in discovering, developing, licensing, manufacturing, and marketing biopharmaceutical products globally. Their portfolio includes treatments for various diseases, including hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and COVID-19. Notable products include Revlimid, which is an oral immunomodulatory drug.
Is BMY stock a good investment in 2026?
While specific valuation metrics such as P/E and revenue growth are currently unavailable, BMY's consistent focus on biopharmaceuticals suggests potential for growth. Investors should consider the company's strong market position in the healthcare sector and its pipeline of innovative drugs, which could enhance its long-term value.
What is Bristol-Myers Squibb Company's market capitalisation and stock price?
Currently, the market capitalization and stock price for Bristol-Myers Squibb Company are not available. Additionally, without concrete figures, we cannot assess the 52-week high and low prices or how they may relate to the company's performance.
Does BMY pay dividends to shareholders?
Bristol-Myers Squibb Company does not currently pay dividends to its shareholders. The absence of dividend payments suggests that the company may be focusing on reinvesting its earnings to fuel growth and innovation.
How profitable is Bristol-Myers Squibb Company?
Specific profitability metrics such as net income, net margin, return on equity, and free cash flow are not available at this time. However, the company's significant workforce of 34,100 employees indicates a robust operational capacity that could support future profitability.
What is BMY's P/E ratio and is the stock overvalued?
Bristol-Myers Squibb Company currently does not have a P/E ratio available for analysis. Without this key valuation metric, it's challenging to determine if the stock is overvalued compared to other companies in the drug manufacturing sector.
How much debt does Bristol-Myers Squibb Company have?
The current debt levels and debt-to-equity ratio for Bristol-Myers Squibb Company are not disclosed. This lack of information makes it difficult to assess the company's balance sheet health and overall financial stability.
What is BMY's 52-week trading range?
At this time, the 52-week trading range for Bristol-Myers Squibb Company is not available. Without this information, we cannot evaluate how the stock's current price compares to its historical performance, including its 50-day and 200-day moving averages.
Is BMY a growth stock or value stock?
Without specific revenue growth or EPS growth data, it's challenging to categorize Bristol-Myers Squibb Company as either a growth or value stock. However, the company's focus on innovative biopharmaceuticals may suggest a growth-oriented investment strategy.
What are the main risks of investing in BMY?
Investing in Bristol-Myers Squibb Company carries certain risks, including its low beta of 0.26, indicating lower volatility compared to the market. Additionally, the competitive landscape in the biopharmaceutical sector poses risks, as does the absence of detailed financial metrics such as debt levels and revenue growth.